Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dutogliptin + filgrastim
- Development stage
- Phase 3
- Lead developer
- Recardio
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Dutogliptin + filgrastim is an investigational combination therapy being evaluated for the treatment of patients recovering from ST-elevation myocardial infarction (STEMI). Dutogliptin is a second-generation small molecule inhibitor of dipeptidyl peptidase-IV (DPP4), which prevents the degradation of stromal cell-derived factor 1α (SDF-1α), a chemokine involved in stem cell homing and tissue repair. Filgrastim, also known as recombinant human granulocyte colony-stimulating factor (G-CSF), is a biologic that stimulates the production and mobilization of neutrophils and hematopoietic stem cells from the bone marrow. The combination aims to enhance endogenous cardiac repair mechanisms by increasing circulating progenitor cells and improving myocardial regeneration after heart attack. This approach has been tested in phase 2 clinical trials for safety, tolerability, and preliminary efficacy in restoring left ventricular function post-myocardial infarction[1][3][5].
- Other names
- G-CSF (for filgrastim)recombinant human granulocyte colony-stimulating factor (for filgrastim)
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)CSF3R (Granulocyte colony-stimulating factor receptor)
Beyond the preview
Go deeper on dutogliptin + filgrastim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dutogliptin + filgrastim.